- Home
- IONR vs CRVO Comparison
IONR vs CRVO Comparison
Compare IONR & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONR
- CRVO
- Stock Information
- Founded
- IONR 2001
- CRVO 2001
- Country
- IONR Australia
- CRVO United States
- Employees
- IONR N/A
- CRVO N/A
- Industry
- IONR
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- IONR
- CRVO Health Care
- Exchange
- IONR Nasdaq
- CRVO Nasdaq
- Market Cap
- IONR 319.2M
- CRVO 98.3M
- IPO Year
- IONR N/A
- CRVO N/A
- Fundamental
- Price
- IONR $4.11
- CRVO $2.13
- Analyst Decision
- IONR
- CRVO Buy
- Analyst Count
- IONR 0
- CRVO 8
- Target Price
- IONR N/A
- CRVO $38.75
- AVG Volume (30 Days)
- IONR 25.0K
- CRVO 476.7K
- Earning Date
- IONR 01-01-0001
- CRVO 11-12-2024
- Dividend Yield
- IONR N/A
- CRVO N/A
- EPS Growth
- IONR N/A
- CRVO N/A
- EPS
- IONR N/A
- CRVO N/A
- Revenue
- IONR N/A
- CRVO $10,066,550.00
- Revenue This Year
- IONR N/A
- CRVO $34.17
- Revenue Next Year
- IONR N/A
- CRVO N/A
- P/E Ratio
- IONR N/A
- CRVO N/A
- Revenue Growth
- IONR N/A
- CRVO 116.29
- 52 Week Low
- IONR $2.90
- CRVO $1.80
- 52 Week High
- IONR $9.35
- CRVO $26.38
- Technical
- Relative Strength Index (RSI)
- IONR 42.24
- CRVO 28.45
- Support Level
- IONR $3.71
- CRVO $1.99
- Resistance Level
- IONR $4.58
- CRVO $2.43
- Average True Range (ATR)
- IONR 0.34
- CRVO 0.17
- MACD
- IONR 0.07
- CRVO 0.31
- Stochastic Oscillator
- IONR 51.04
- CRVO 26.92
About IONR ioneer Ltd
Ioneer Ltd is a mineral exploration company. The company's focus is on the Rhyolite Ridge Lithium-Boron Project located in Nevada, USA. Geographically, the group has a business presence in Australia and North America. The company's focus is to develop a U.S.-based source of lithium and boron that can be extracted in an environmentally and socially responsible manner, providing two materials that are essential to achieve a sustainable future for the planet.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.